Novo Nordisk Expands Wegovy® Access Through Telehealth Partnerships
Krissy Vann | Host, All Things Fitness and Wellness
Novo Nordisk is broadening access to its weight loss medication Wegovy® by partnering with several telehealth providers, marking a strategic shift to meet growing demand in the U.S. obesity market. The company announced today that patients of Hims & Hers Health, Inc., LifeMD, and Ro can now obtain authentic, FDA-approved Wegovy® directly through NovoCare® Pharmacy via a streamlined process.
Wegovy®, which has been in full supply since March 2025, is available to self-paying patients for $499 per month. CenterWell Pharmacy handles prescription fulfillment and shipping for NovoCare® Pharmacy, offering home delivery for all dose strengths.
“Wegovy® continues to be in high demand as there are 100 million Americans living with obesity,” said Dave Moore, Executive Vice President of U.S. Operations and President of Novo Nordisk Inc. in a statement. “We believe patients living with this chronic disease who want and need treatment under the care of a licensed healthcare professional, including those embracing the growing telehealth community, deserve to get the real thing.”
Originally approved by the U.S. Food and Drug Administration (FDA) in 2021, Wegovy® was the first GLP-1 treatment authorized for chronic weight management through a once-weekly injection. In 2024, the FDA expanded the drug’s label to include an indication for reducing the risk of major cardiovascular events in adults with obesity or overweight who have existing heart disease.
The latest partnerships allow patients using telehealth services to access Wegovy® through a simplified pathway without navigating traditional pharmacy networks. This move comes as Novo Nordisk seeks to address logistical barriers that have historically made accessing GLP-1 medications challenging for many patients.
Wegovy® is currently prescribed to nearly 1.5 million patients across the United States, according to the company. The $499-per-month price point applies both to prescriptions filled through NovoCare® Pharmacy and, via savings offers, at participating retail pharmacies.
While Novo Nordisk is best known for its leadership in diabetes care, the company has increasingly shifted focus to the obesity treatment market, which industry analysts project will continue to grow rapidly over the next decade. Expanding direct-to-patient and telehealth channels appears to be a central component of that strategy.
“Making Wegovy® available via these telehealth channels, with its clinically-tested weight loss in its premium pen delivery device, is an important step forward in allowing patients to receive care in the way they choose and helping them to achieve their weight loss goals with an authentic, FDA-approved medicine,” Moore added.
Wegovy® and the semaglutide molecule continue to undergo clinical evaluation for additional uses across a variety of chronic conditions beyond obesity and cardiovascular health.
Novo Nordisk indicated it will continue exploring partnerships and pathways to increase accessibility to its obesity treatments as competition in the GLP-1 category intensifies.
Credit: Novo Nordisk